Table 6. Discharge medications of non-obese and obese NVCM patients.
NVCM: non-valvular cardiomyopathy; ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker
| Variable | Non-obese 395 (63%) | Obese 231 (37%) | P-value |
| Sacubtril/valsartan (Entresto), N (%) | 103 (26%) | 79 (34%) | 0.062 |
| ACEi/ARBs, N (%) | 241 (61%) | 120 (52%) | 0.052 |
| Aspirin, N (%) | 336 (85%) | 192 (83%) | 0.460 |
| Clopidogrel, N (%) | 245 (62%) | 125 (54%) | 0.070 |
| Beta-blockers, N (%) | 363 (92%) | 206 (89%) | 0.352 |
| Statin, N (%) | 312 (79%) | 188 (81%) | 0.662 |
| Loop diuretics, N (%) | 304 (77%) | 180 (78%) | 0.726 |
| Spironolactone, N (%) | 268 (68%) | 162 (70%) | 0.613 |
| Metolazone, N (%) | 20 (5%) | 14 (6%) | 0.570 |
| Nitrates, N (%) | 107 (27%) | 56 (24%) | 0.494 |
| Digoxin, N (%) | 12 (3%) | 14 (6%) | 0.086 |